electroCore, Inc. ECOR

ROCKAWAY, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the H.C. Wainwright 28th Annual Global Investment Conference at the Lotte New York Palace Hotel. On Tuesday, September 15, 2026, Joshua Lev, Co-CEO, President and CFO, will participate in a fireside chat and host one-on-one meetings with investors during the conference. Investors who wish to reques

Internal leadership appointments reflect the Company's confidence in two exceptional leaders whose complementary strengths will enhance shareholder valueROCKAWAY, N.J., Sept. 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today announced that it has appointed Joshua Lev and Mike Fox as Co-Chief Executive Officers and members of the Board of Directors, ef

LONDON, UK / ACCESS Newswire / September 7, 2026 / Ecora (LSE:ECOR)(TSX:ECOR)(OTCQX:ECRAF), announces that its registered office has changed with immediate effect. The Company's new registered office address is: Carrington House 1st Floor West 126 - 130 Regent Street London W1B 5SEAll other Company contact details, including telephone numbers and website address, remain unchanged.

LONDON, UK / ACCESS Newswire / September 3, 2026 / Ecora (LSE/TSX:ECOR)(OTCQX:ECRAF) is pleased to announce that the leadership team will host a live interactive presentation to discuss the recent 2026 Half Year Results on the Engage Investor platform, on Thursday 10th September 2026, at 2pm BST.Ecora welcomes all current shareholders and interested investors to join and encourages investors to pre-submit questions.

Ecora Resources (LON:ECOR) reported a strong first half of 2026, driven by growth in its base-metals portfolio, higher commodity prices and continued ramp-ups at key operating assets. Total portfolio contribution rose 75% year over year to £31.3 million, from £17.9 million, while base-metals contri

Strong performance builds on momentum from 2025LONDON, UK / ACCESS Newswire / September 2, 2026 / (LSE:ECOR)(TSX:ECOR)(OTCQX:ECRAF) announces half year results for the six months ended 30 June 2026 which are available on the Group's website at www. All currencies referred to within are in US dollars unless otherwise specified.

Recognition highlights Truvaga’s combination of patented non-invasive vagus nerve stimulation technology, thoughtful design and personalized wellness experienceROCKAWAY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a bioelectronic technology company, today announced that Truvaga, its non-invasive vagus nerve stimulation (nVNS) wellness brand, has been named the 2026 Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards. The award recognizes T

electroCore (ECOR) delivered earnings and revenue surprises of +19.51% and +0.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Second quarter 2026 net sales of $9.5 million, an increase of 28% over $7.4 million in the second quarter 2025 Net loss of $3.1 million decreased 17% from prior year with Adjusted EBITDA net loss improving 26% from prior-year period Increasing 2026 revenue guidance to greater than 30% year-over-year growth Company to host a conference call and webcast today, August 6, 2026, at 4:30 pm EDT ROCKAWAY, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Co

ROCKAWAY, N.J., Aug. 03, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the following investor conferences: Needham 11th Annual Virtual MedTech and Diagnostics Conference, taking place virtually on Tuesday, August 11, 2026. Management will host one-on-one meetings virtually.Canaccord Genuity 46th Annual Growth Conference, taking place in Boston, Massachusetts, on Tuesda

ROCKAWAY, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the second quarter ended June 30, 2026, after the close of the market on Thursday, August 6, 2026. Management will host a webinar at 4:30 PM EDT to review the financial results and answer questions. Investors can access the webinar using the details below: Thursday, August 6, 4:30 PM EDTDial-I

Ecora Royalties PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF, FRA:HGR) reported that its quarterly portfolio contribution jumped 61% year-on-year to US$19 million, driven by record cobalt receipts from the Voisey’s Bay operation. Base metals generated US$14.1 million, up 166% and accounting for...

LONDON / ACCESS Newswire / July 29, 2026 / Ecora (LSE:ECOR)(TSX:ECOR)(OTCQX:ECRAF) issues the following trading update for the period 1 April to 30 June 2026. Marc Bishop Lafleche, Chief Executive Officer of Ecora, commented: "Q2 was a strong quarter, ...

ROCKAWAY, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today announced the publication of the peer-reviewed review article, "Two Paths to the Body's Superhighway—The Auricular Branch (taVNS) and the Cervical Bundle (tcVNS): A Narrative Review," in Frontiers in Neuroscience. The article was authored by Peter S. Staats, MD, MBA, Chief Medical

RALEIGH, NC / ACCESS Newswire / June 23, 2026 / iAccess Alpha's Virtual Best Ideas Summer Investment Conference begins today, bringing together small and micro-cap public companies and investors for a full day of company presentations, followed by ...

RALEIGH, NC / ACCESS Newswire / June 18, 2026 / iAccess Alpha today announced that it will host its Virtual Best Ideas Summer Investment Conference on June 23-24, 2026, bringing together small and micro-cap public companies and investors for two days ...

The fair value price target for Ecora Royalties has been adjusted slightly, moving from £1.71 to £1.72 as the latest assumptions are fed into analyst models. This small change comes alongside a mix of bullish and bearish commentary, with some analysts framing it as a fine tuning of expectations and others highlighting reduced valuation cushion. Read on to see what is driving the evolving narrative and how you can keep track of these shifting assumptions over time. Analyst Price Targets don't...